<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554681</url>
  </required_header>
  <id_info>
    <org_study_id>2016.152</org_study_id>
    <nct_id>NCT03554681</nct_id>
  </id_info>
  <brief_title>Prediction of Preeclampsia (PE) at 11-13 Week</brief_title>
  <official_title>Prospective Validation of Prediction Algorithms for Preeclampsia in the First-trimester of Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiu Yee Liona Poon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international multicentre prospective cohort study to validate the Bayes theorem
      based algorithms for the screening of pre-eclampsia (PE) in the first-trimester of pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have previously constructed Bayes model in the first-trimester which
      combines maternal characteristics and medical history (Mat-CH) together with mean arterial
      pressure (MAP), uterine artery pulsatility index (PI), and serum placental growth factor
      (PlGF) with a plan to assess the predictive performance.

      The reference standards will be PE defined according to the International Society for the
      Study of Hypertension in Pregnancy and the American College of Obstetricians and
      Gynecologists. The systolic blood pressure should be &gt;140 mm Hg and/or the diastolic blood
      pressure should be &gt;90 mmHg on at least two occasions four hours apart developing after 20
      weeks' gestation in previously normotensive women and there should be proteinuria (&gt;300 mg in
      24 hours or two readings of at &gt;2+ on dipstick analysis of midstream or catheter urine
      specimens if no 24-hour collection is available). In the absence of proteinuria, new onset of
      any of the following systemic findings: a) thrombocytopaenia (platelet counts &lt;100,000 µL);
      b) renal insufficiency (creatinine &gt;1.1 mg/dL or 2-fold increase in creatinine in the absence
      of underlying renal disease); c) abnormal liver function (ie, hepatic transaminase levels
      twice normal); d) pulmonary oedema; or e) cerebral or visual symptoms. Preterm-PE is PE that
      requires delivery before 37 weeks' gestation. If a participant fulfills the criteria for PE
      by one definition and not the other she will be considered to have developed PE.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The false positive and true positive frequencies for screening for PE using the Bayes theorem based methods</measure>
    <time_frame>At delivery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The false positive and true positive frequencies for screening of delivery of all-Small for Gestational Age (SGA) neonates and preterm-SGA neonates (delivery before 37 weeks), with or without PE</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">10935</enrollment>
  <condition>Pre-Eclampsia</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      An additional blood 5ml sample, if agreed to by the study participant, for recovery of plasma
      for future research will be taken and archived at -80℃.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All eligible women attending for their hospital visit at 11-13 weeks will be invited to
        participate.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 18 years

          -  Singleton pregnancy

          -  Live fetus

          -  Provide Informed and written consent in the official language of the country

        Exclusion Criteria:

          -  Unable to provide written Informed consent learning difficulties or serious mental
             illness or an inability to understand spoken and written the official language of the
             country.

          -  Multiple Pregnancy

          -  Non-viable fetus (missed spontaneous abortion or stillbirth)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liona CY Poon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kwong Wah Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mediscan Chennai</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyama University Hospital</name>
      <address>
        <city>Toyama</city>
        <state>Toyama Prefecture</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Fetal Medicine PMC</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated hospitals within The Japan Society for the Study of Hypertension in Pregnancy (JSSHP)</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Chang Gung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University Bangkok</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Japan</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>National Collaborating Centre for Women's and Children's Health (UK). Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. London: RCOG Press; 2010 Aug.</citation>
    <PMID>22220321</PMID>
  </reference>
  <reference>
    <citation>Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007 May 26;369(9575):1791-1798. doi: 10.1016/S0140-6736(07)60712-0. Review.</citation>
    <PMID>17512048</PMID>
  </reference>
  <reference>
    <citation>Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguère Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010 Aug;116(2 Pt 1):402-14. doi: 10.1097/AOG.0b013e3181e9322a.</citation>
    <PMID>20664402</PMID>
  </reference>
  <reference>
    <citation>Roberge S, Villa P, Nicolaides K, Giguère Y, Vainio M, Bakthi A, Ebrashy A, Bujold E. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther. 2012;31(3):141-6. doi: 10.1159/000336662. Epub 2012 Mar 21. Review.</citation>
    <PMID>22441437</PMID>
  </reference>
  <reference>
    <citation>Roberge S, Giguère Y, Villa P, Nicolaides K, Vainio M, Forest JC, von Dadelszen P, Vaiman D, Tapp S, Bujold E. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol. 2012 Aug;29(7):551-6. doi: 10.1055/s-0032-1310527. Epub 2012 Apr 11. Review. Erratum in: Am J Perinatol. 2014 Jun;31(6):e3. von Dadelzen, Peter [corrected to von Dadelszen, Peter].</citation>
    <PMID>22495898</PMID>
  </reference>
  <reference>
    <citation>Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol. 2015 Jul;213(1):62.e1-62.e10. doi: 10.1016/j.ajog.2015.02.018. Epub 2015 Feb 25.</citation>
    <PMID>25724400</PMID>
  </reference>
  <reference>
    <citation>O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016 Jan;214(1):103.e1-103.e12. doi: 10.1016/j.ajog.2015.08.034. Epub 2015 Aug 19.</citation>
    <PMID>26297382</PMID>
  </reference>
  <reference>
    <citation>Gallo DM, Wright D, Casanova C, Campanero M, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation. Am J Obstet Gynecol. 2016 May;214(5):619.e1-619.e17. doi: 10.1016/j.ajog.2015.11.016. Epub 2015 Nov 25.</citation>
    <PMID>26627730</PMID>
  </reference>
  <reference>
    <citation>Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation. Am J Obstet Gynecol. 2016 Jul;215(1):87.e1-87.e17. doi: 10.1016/j.ajog.2016.02.016. Epub 2016 Feb 12.</citation>
    <PMID>26875953</PMID>
  </reference>
  <reference>
    <citation>Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH. Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation. Ultrasound Obstet Gynecol. 2016 Jul;48(1):72-9. doi: 10.1002/uog.15812. Epub 2016 May 30.</citation>
    <PMID>26566592</PMID>
  </reference>
  <reference>
    <citation>Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20(1):IX-XIV. Review.</citation>
    <PMID>12044323</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-31. doi: 10.1097/01.AOG.0000437382.03963.88.</citation>
    <PMID>24150027</PMID>
  </reference>
  <reference>
    <citation>Snijders RJ, Nicolaides KH. Fetal biometry at 14-40 weeks' gestation. Ultrasound Obstet Gynecol. 1994 Jan 1;4(1):34-48.</citation>
    <PMID>12797224</PMID>
  </reference>
  <reference>
    <citation>Acharya G, Wilsgaard T, Berntsen GK, Maltau JM, Kiserud T. Reference ranges for serial measurements of umbilical artery Doppler indices in the second half of pregnancy. Am J Obstet Gynecol. 2005 Mar;192(3):937-44.</citation>
    <PMID>15746695</PMID>
  </reference>
  <reference>
    <citation>Vyas S, Campbell S, Bower S, Nicolaides KH. Maternal abdominal pressure alters fetal cerebral blood flow. Br J Obstet Gynaecol. 1990 Aug;97(8):740-2.</citation>
    <PMID>2205291</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 9, 2018</study_first_submitted>
  <study_first_submitted_qc>June 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>December 31, 2019</last_update_submitted>
  <last_update_submitted_qc>December 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Chiu Yee Liona Poon</investigator_full_name>
    <investigator_title>Associate Professor (Clinical)</investigator_title>
  </responsible_party>
  <keyword>Bayes Model</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

